Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

T4 Oesophageal Resection.

- candidate number10321
- NTR NumberNTR3060
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR6-sep-2011
- Secondary IDs11_019 METC AMC
- Public TitleT4 Oesophageal Resection.
- Scientific TitleChemoradiation followed by surgery for patients with cT4 oesophageal carcinoma.
- hypothesisPatients with T4-irresectable carcinoma are generally treated with definitive chemoradiotherapy without curative intent. Considering the positive results of neoadjuvant chemotherapy followed by surgery, we hypothesize that chemoradiotherapy can reduce the size of T4 tumors and allows for surgical resection of the esophagus and an improved survival rate.
- Healt Condition(s) or Problem(s) studiedEsophageal cancer, Oesophagectomy, Chemoradiotherapy, T4 tumor
- Inclusion criteria1. Histologically proven squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma of the intrathoracic esophagus or gastroesophageal junction;
2. Surgically irresectable T4 carcinoma as determined by endoscopic ultrasonography (EUS), CT scan or PET-CT of neck, thorax and abdomen, without distant mestastases.
- Exclusion criteria1. cT4 carcinoma with tracheobronchial involvement demonstrated on bronchoscopy after chemoradiotherapy;
2. Past or current history of malignancy other than entry diagnosis except for non-melanomatous skin cancer, or curatively treated in situ carcinoma of the cervix, or malignancy more than 5 years prior to enrollment;
3. Pregnancy (positive serum pregnancy test) and lactation;
4. Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) <1 year before enrollment;
5. Active infection or other serious underlying medical condition which would impair the ability of the patient to receive the planned treatment;
6. Dementia or altered mental status that would prohibit the understanding and giving of informed consent;
7. Inadequate caloric and/or fluid intake Weight loss >15%.
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeintervention
- planned startdate 6-jul-2011
- planned closingdate1-feb-2013
- Target number of participants30
- InterventionsSurgery after chemoradiotherapy: Transthoracic esophagal resection (open, right thoracotomy) with en-bloc two-field lymphadenectomy.
- Primary outcomeThe ability to achieve a radical (R0) resection.
- Secondary outcome1. Toxicity profile of chemoradiotherapy;
2. Adequacy of PET-CT and EUS in (re)staging T4 esophageal carcinoma;
3. Peri-operative morbidity and mortality;
4. Percentage of pathologic complete response;
5. Progression free survival at 6 months.
- TimepointsPatients will fill out questionnaires regarding quality of life on 6 occasions; prior to chemoradiotherapy, prior to surgery, 6 weeks postoperatively and 3, 6, 12 months after surgery.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT for SCIENTIFIC QUERIESDr. M.I. Berge Henegouwen, van
- Sponsor/Initiator Academic Medical Center (AMC), Department of Surgery
- Funding
(Source(s) of Monetary or Material Support)
Academic Medical Center (AMC), Amsterdam
- PublicationsN/A
- Brief summaryRationale:
Current treatment of cT4 (locally irresectable) esophageal carcinoma is subject of debate, but mostly consists of chemoradiotherapy (CRT). However, the results of definite CRT in cT4 esopahgeal carcinoma remain poor with only 20% of patients alive at 3 years after start of CRT and a local recurrence rate up to 60% without any curative options and with an infaust prognosis. Local control and survival might be improved by surgical resection following CRT for cT4 esophageal carcinoma. Only small series concerning this topic exist at present time, suggesting feasibility and improved local control.

To assess the feasibility of surgery following CRT in patients with cT4 esophageal carcinoma with regard to morbidity, mortality and the possibility to achieve a R0 resection.

Study design:
Phase II, non-randomized trial.

Study population:
Patients with cT4 irresectable esophageal carcinoma (adenocarcinoma, squamous cell carcinoma or undifferentiated carcinoma) of the intrathoracic esophagus or gastroesophageal junction, aged >18 <75 years.

Esophagectomy after chemoradiotherapy.

Main endpoints:
The ability to achieve a radical (R0) resection. Secondary endpoint are toxicity profile, adequacy of PET-CT and EUS in (re-)staging T4 esophageal carcinoma, perioperative morbidity and mortality, percentage of pathologic complete response, progression free survival at 6 months.
- Main changes (audit trail)
- RECORD6-sep-2011 - 25-sep-2011

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar